Analysis of curative effect of paclitaxel and zoledronic acid in the treatment of malignant bone tumors
Objective To analyze the effect of paclitaxel and zoledronic acid in the treatment of malignant bone tumors.Methods 84 patients with malignant bone tumor were randomly divided into a conventional group and a study group,with 42 cases in each group.The conventional group was treated with paclitaxel,and the study group was treated with paclitaxel and zoledronic acid.The efficacy,adverse reactions,analgesic effect,pain intensity,quality of life,blood routine index,serum carcinoembryonic antigen and blood calcium levels were compared between the two groups.Results The total effective rate was 95.24%in the study group,which was higher than 78.57%in the conventional group(P<0.05).The incidence of adverse reactions was 4.76%in the study group,which was lower than 23.81%in the conventional group(P<0.05).The total effective rate of analgesia was 92.86%in the study group and 76.19%in the conventional group(P<0.05).The visual analogue scale(VAS)scores of the study group at 3,6 and 12 months after treatment were(1.24±0.62),(1.25±0.41)and(0.65±0.33)points,which were lower than(3.65±1.34),(2.67±1.68)and(2.35±1.46)points of the conventional group(P<0.05).After treatment,the scores of social function,physical function,material function and psychological function were(79.81±7.26),(87.69±7.45),(85.41±6.28)and(85.37±7.69)points in the study group,which were higher than(70.21±6.24),(75.31±6.58),(74.24±6.85)and(77.15±7.08)points in the conventional group(P<0.05).After treatment,the white blood cell count,hemoglobin count and platelet count of the study group were(7.20±1.21)×109/L,(126.78±12.26)g/L,and(145.47±23.74)×109/L,which were higher than(5.39±2.29)×109/L,(100.25±13.17)g/L and(118.47±30.25)×109/L of the conventional group(P<0.05).After treatment,the levels of serum carcinoembryonic antigen and blood calcium in the study group were(35.54±11.60)ng/ml and(2.16±0.20)mmol/L,which were lower than(44.42±11.65)ng/ml and(2.47±0.64)mmol/L in the conventional group(P<0.05).Conclusion The combined treatment of paclitaxel and zoledronic acid for patients with malignant bone tumors can reduce the pain of patients with good analgesic effect,and can improve the blood routine indicators,serum carcinoembryonic antigen and blood calcium levels of patients with fewer adverse reactions,significantly improve the quality of life of patients,and the efficacy is obvious,which can be vigorously promoted.
PaclitaxelZoledronic acidMalignant bone tumorsCurative effect
NETL
NSTL
万方数据
